Company intelligence / Profile preview

Azafaros

Naarden*, North Holland / Zuid-Holland region likely*, Netherlandsazafaros.com ↗

Ownership: Private
Employees: ~23
Development stage: Phase 3

Overview

Azafaros has completed both Phase I and II studies with its lead candidate nizubaglustat, an oral small molecule targeting neurological lysosomal storage disorders. The company has also run a multinational natural history study to support future clinical development. Regulatory clearance for global Phase III studies was granted by European authorities in early 2025, with trial initiation planned the same year.

Therapeutic areas: Rare Diseases
Modalities: Small molecules (specifically, orally available azasugars)
Industry: Biotech

Drug pipeline

1 asset

nizubaglustat

Partnerships

No major pharma partnerships disclosed. Supported by leading investors and collaborations with academic institutions such as Leiden University and Amsterdam UMC.

Beyond the preview

Go deeper on Azafaros.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Azafaros.